XNASANEB
Market cap42mUSD
Jan 07, Last price
1.64USD
1D
1.24%
1Q
-15.90%
IPO
-76.74%
Name
Anebulo Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-8m
L-30.09%
CFO
-8m
L-16.44%
Earnings
Feb 11, 2025
Profile
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 8,309 | 11,784 | 6,831 | ||
Unusual Expense (Income) | |||||
NOPBT | (8,309) | (11,784) | (6,831) | ||
NOPBT Margin | |||||
Operating Taxes | (13) | ||||
Tax Rate | |||||
NOPAT | (8,309) | (11,784) | (6,818) | ||
Net income | (8,202) -30.09% | (11,732) 72.21% | (6,813) -77.49% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 654 | 6,647 | |||
BB yield | -0.93% | -11.28% | |||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (3,094) | (11,247) | (14,548) | ||
| Cash flow | |||||
Cash from operating activities | (8,091) | (9,683) | (5,437) | ||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | (62) | 6,382 | |||
FCF | (8,462) | (11,265) | (5,911) | ||
| Balance | |||||
Cash | 3,094 | 11,247 | 14,548 | ||
Long term investments | |||||
Excess cash | 3,094 | 11,247 | 14,548 | ||
Stockholders' equity | (65,378) | (57,176) | (45,446) | ||
Invested Capital | 69,190 | 67,778 | 60,513 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 25,822 | 25,074 | 23,345 | ||
Price | 2.73 16.17% | 2.35 -54.81% | 5.20 -23.75% | ||
Market cap | 70,495 19.63% | 58,925 -51.46% | 121,392 -23.75% | ||
EV | 67,401 | 47,678 | 106,843 | ||
EBITDA | (8,309) | (11,784) | (6,831) | ||
EV/EBITDA | |||||
Interest | 7 | ||||
Interest/NOPBT | |||||